published meta-analysis   sensitivity analysis   studies

anti-interleukin-6 in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCORIMUNO-19, 2020 0.92 [0.31; 2.71] EMPACTA, 2020 1.13 [0.54; 2.40] 1.06[0.57; 1.96]CORIMUNO-19, 2020, EMPACTA, 202020%507moderatenot evaluable clinical deteriorationdetailed resultsCORIMUNO-19, 2020 0.56 [0.26; 1.20] EMPACTA, 2020 0.55 [0.33; 0.92] 0.55[0.36; 0.85]CORIMUNO-19, 2020, EMPACTA, 202020%130moderatenot evaluable clinical improvementdetailed resultsEMPACTA, 2020 1.15 [0.90; 1.47] 1.15[0.90; 1.47]EMPACTA, 202010%moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsEMPACTA, 2020 1.15 [0.90; 1.47] 1.15[0.90; 1.47]EMPACTA, 202010%moderatenot evaluable death or ventilationdetailed resultsCORIMUNO-19, 2020 0.56 [0.24; 1.31] EMPACTA, 2020 0.56 [0.32; 0.97] 0.56[0.35; 0.89]CORIMUNO-19, 2020, EMPACTA, 202020%131moderatenot evaluable hospital dischargedetailed resultsEMPACTA, 2020 1.16 [0.90; 1.49] 1.16[0.90; 1.49]EMPACTA, 202010%moderatenot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2021-01-18 08:58 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 557,635,553,628,646,645,607,395 - roots T: 290